U.S., Aug. 6 -- ClinicalTrials.gov registry received information related to the study (NCT07104812) titled 'Impact of 1 mg Osilodrostat Therapy on Mild Autonomous Cortisol Secretion (MACS)' on July 29.
Brief Summary: The purpose of this study is to evaluate the safety and tolerability of 1 mg osilodrostat therapy in patients with mild autonomous cortisol secretion (MACS), and to determine the impact on 24h urine steroid metabolome and circadian cortisol/cortisone concentrations
Study Start Date: Jan., 2026
Study Type: INTERVENTIONAL
Condition:
Mild Autonomous Cortisol Secretion
Autonomous Cortisol Secretion (ACS)
Intervention:
DRUG: Osilodrostat 1 MG
Osilodrostat 1 mg administered between noon and 6 pm daily, for 4 weeks
Recruitmen...